ALK’s ACARIZAX® Tablet Gains NICE Approval in the UK
ALK (ALKB:DC / OMX: ALK B / AKBLF) recently announced significant news regarding its ACARIZAX® tablet, which has been recommended by the National Institute for Health and Care Excellence (NICE). This recommendation opens the door for patients suffering from persistent, moderate to severe house dust mite allergic rhinitis to receive ACARIZAX® through the National Health Service (NHS) in England, Wales, and Northern Ireland. Consequently, this makes the treatment eligible for general reimbursement, benefiting countless individuals affected by this condition.
First Sublingual Allergy Immunotherapy to Gain Approval
ACARIZAX® holds the distinction of being the first sublingual allergy immunotherapy (AIT) product that NICE has assessed and endorsed. This pivotal development signifies its widespread availability within the NHS framework. As of now, the UK remains one of the few European markets where ALK’s allergy tablets lack adequate public reimbursement, highlighting a significant gap that this recommendation is poised to fill. Moreover, allergic immunotherapy is generally underutilised in the UK compared to other European nations, making this milestone even more critical.
NICE Approval a Landmark Moment
ALK’s Executive Vice President of Commercial Operations, Søren Niegel, expressed his enthusiasm about the approval: “Today’s news marks a milestone for ALK. NICE’s methodologies and guidelines are widely regarded as the gold standard, and we are proud to be the first and only company offering sublingual allergy immunotherapy tablets across the United Kingdom for the many patients whose lives are profoundly affected by allergies.” This endorsement reflects the growing recognition of allergenic conditions and the necessity of effective treatment.
The Prevalence of Allergic Rhinitis
Allergic rhinitis is a common concern in the UK, impacting approximately 26% of adults. For many of these individuals, house dust mites are identified as the most prevalent airborne allergens. It is estimated that nearly half of those suffering from allergic rhinitis—over 5 million individuals—are affected by dust mite allergies. Unfortunately, despite the availability of various symptomatic treatments, around one million people endure debilitating and uncontrolled symptoms that significantly diminish their quality of life.
NICE’s Review Process and Future Directions
NICE plays a crucial role in evaluating the clinical benefits and cost-effectiveness of healthcare interventions. They published a Final Draft Guidance document detailing the assessment of ACARIZAX® as an effective treatment option for uncontrolled house dust mite allergies. Following this, a Final Guidance publication is anticipated, following which NHS systems in England, Wales, and Northern Ireland will implement ACARIZAX® in their treatment practices. Alongside this, ALK aims to submit another application for a NICE review of its sublingual tree tablet, ITULAZAX®, and is also looking to expand approvals for both ACARIZAX® and ITULAZAX® to include treatments for children.
Current Focus and Future Growth
ALK’s operations in the UK currently emphasize anaphylaxis treatments, notably through its adrenaline pen Jext®, which is on the market, and a nasal spray called EURneffy®, slated for launch pending regulatory approval. Although the sales of AIT tablets are modest, ALK anticipates fostering synergies between its anaphylaxis products and its allergy tablets as awareness grows and infrastructure expands. These efforts are designed to bolster access and enhance overall treatment options for patients.
Looking Ahead After NICE Approval
While the NICE approval is a landmark achievement for ALK, it is not projected to influence the company's revenue growth immediately. However, the potential for increased patient access to ACARIZAX® may lead to long-term benefits.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergies and those who treat allergies. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 individuals globally and is listed on Nasdaq Copenhagen. More information can be found at www.alk.net.
Frequently Asked Questions
What is ACARIZAX®?
ACARIZAX® is the first sublingual allergy immunotherapy tablet recommended by NICE for treating moderate to severe house dust mite allergic rhinitis.
How does this NICE recommendation benefit patients?
This recommendation allows patients to access ACARIZAX® through the NHS, making it eligible for reimbursement and improving treatment options.
What is the prevalence of allergic rhinitis in the UK?
Approximately 26% of adults in the UK are affected by allergic rhinitis, with house dust mites being a leading cause.
What are the next steps following the NICE approval?
NICE plans to publish a Final Guidance, after which ACARIZAX® will be implemented in NHS treatment practices.
What other products does ALK offer?
ALK also offers an adrenaline pen for anaphylaxis (Jext®) and plans to launch a nasal spray (EURneffy®). Additionally, they are pursuing further immunotherapy tablets for broader indications.
